AI assistant
Sending…
RemeGen Co., Ltd. — Board/Management Information 2021
Jun 1, 2021
51206_rns_2021-06-01_f671fc18-cd7d-4e7c-956f-0991f6dbee1c.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [112 x 39] intentionally omitted <==
RemeGen Co., Ltd.[*]
榮 昌 生 物 製 藥( 煙 台 )股 份 有 限 公 司 (the ‘‘Company’’)
(A joint stock company incorporated in the People’s Republic of China with limited liability)
(Stock Code: 9995)
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
The members of the board of directors (the ‘‘Board’’) of the Company are set out below:
Executive Directors
-
Mr. Wang Weidong (Chairman of the Board)
-
Dr. Fang Jianmin
-
Dr. He Ruyi
-
Mr. Lin Jian
Non-executive Directors
-
Dr. Wang Liqiang
-
Dr. Su Xiaodi
Independent non-executive Directors
-
Ms. Yu Shanshan
-
Mr. Hao Xianjing
-
Dr. Ma Lan
– 1 –
There are four Board committees. The composition of the Board committees is set out in the table below:
| the table below: | the table below: | |||||
|---|---|---|---|---|---|---|
| Committee Director |
Strategy Committee |
|||||
| Committee Director |
Audit Committee |
Remuneration and Appraisal Committee |
Nomination Committee |
Strategy Committee |
||
| Mr. Wang Weidong | — | — | C | M | ||
| Dr. Fang Jianmin | — | — | — | C | ||
| Dr. He Ruyi | — | — | — | M | ||
| Mr. Lin Jian | — | M | — | — | ||
| Dr. Wang Liqiang | M | — | — | M | ||
| Dr. Su Xiaodi | — | — | — | M | ||
| Ms. Yu Shanshan | M | C | M | — | ||
| Mr. Hao Xianjing | C | M | M | — | ||
| Dr. Ma Lan | Dr. Ma Lan | — | — | — | — | |
Notes:
- C Chairperson of the relevant Board committees M Member of the relevant Board committees
Yantai, The People’s Republic of China June 1, 2021
- For identification purpose only
– 2 –
More from RemeGen Co., Ltd.
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 20
Proxy Solicitation & Information Statement
2026
May 20
Regulatory Filings
2026
May 19
Regulatory Filings
2026
May 19
Governance Information
2026
May 18
Governance Information
2026
May 18
Board/Management Information
2026
May 18
Capital/Financing Update
2026
May 18
Proxy Solicitation & Information Statement
2026
May 18